Publication Name	World Journal of Gastroenterology
Manuscript ID	9559
Country	China

Received	2014-02-17 16:43
Peer-Review Started	2014-02-17 20:02
To Make the First Decision	2014-03-27 21:15
Return for Revision	2014-03-31 10:06
Revised	2014-04-28 00:00
Second Decision	2014-05-26 21:30
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2014-05-26 21:49
Articles in Press	2014-05-26 22:05
Publication Fee Transferred
Edit the Manuscript by Language Editor	2014-06-18 22:35
Typeset the Manuscript	2014-11-28 16:54
Publish the Manuscript Online	2014-12-02 10:46

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Autobiography
Article Title	Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats
Manuscript Source	Unsolicited Manuscript
All Author List	Qing-Hong Du, Lin Han, Jun-Jie Jiang, Ya Xu, Wei-Hong Li, Peng-Tao Li, Xin-Yue Wang and Xu Jia
Funding Agency and Grant Number	Funding Agency Grant Number National Key New Drug Creation Project of China 2009ZX09102 National Natural Science Foundation of China 81273885
Corresponding Author	Wei-Hong Li, MD, School of Fundamental Medicine, Beijing University of Chinese Medicine, 11 Bei San Huan Dong Lu, Beijing 100029, China. liweihong.403@163.com
Key Words	Glytan; Portal hypertension; Hemodynamics; Mesentery; Endothelin-1; Receptor; Sensitivity
Core Tip	The traditional Chinese medicine Glytan is composed of salvianolic acid B and diammonium glycyrrhizinate. Previous studies have shown that Glytan is a new preparation for portal hypertension. The present study indicated that decreases in portal pressure and portal territory blood flow observed after Glytan treatment in portal hypertensive rats were related to increased mesenteric endothelin-1 content and reduced endothelin B receptor, endothelial NO synthase, G-protein-coupled receptor kinase 2, and ?-arrestin 2 expression, which may promote mesenteric vasoconstriction and increase receptor sensitivity to vasoconstrictors. These results suggest the therapeutic potential of Glytan in portal hypertension induced by liver cirrhosis.
Publish Date	2014-12-02 10:46
Citation	Du QH, Han L, Jiang JJ, Xu Y, Li WH, Li PT, Wang XY, Jia X. Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats. World J Gastroenterol 2014; 20(44): 16674-16682
URL	http://www.wjgnet.com/1007-9327/full/v20/i44/16674.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i44.16674

Full Article (PDF)	WJG-20-16674.pdf
Full Article (Word)	WJG-20-16674.doc
Manuscript File	9559-Review.doc
Answering Reviewers	9559-Answering reviewers.pdf
Copyright License Agreement	9559-Copyright assignment.pdf
Peer-review Report	9559-Peer review.pdf
Scientific Misconduct Check	9559-CrossCheck.jpg
Scientific Editor Work List	9559-Scientific editor work list.pdf